Skip to main content

Advertisement

Table 2 Studies identified by the systematic review and eligible for inclusion in the NMA

From: A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

Author Study setting Duration, weeks N, randomised Class Study armsa, treatment and dose (n) SU background during trial Pre-trial SU use
Buse[61] US 30 377 GLP-1 1) exenatide 5 μg BID (125); Unchanged from baseline SUb,c At least the maximally effective dose of a SUc as monotherapy for ≥3 months before screening
  2) exenatide 10 μg BID (129);  
  3) placebo BID (123)  
Garber[62] US, Sweden, Finland, Argentina, Lithuania 24 515 DPP-4 1) vildagliptin 50 mg QD (170); Glimepiride 4 mg QD, reduced to 2 mg QD if hypoglycaemia occurred ≥7.5 mg glyburide or glipizide QD, or ≥2 mg glimepiride or equivalent, treated for >3 months with stable dose for ≥4 weeks before screening, switched to glimepiride 4 mg QD for 4 weeks prior to baseline
2) vildagliptin 100 mg QD (169);
3) placebo QD (176)
Hermansen[63] Multi-country 24 212d DPP-4 1) sitagliptin 100 mg QD (106); Stable dose of glimepiride (4 mg – 8 mg QD) A stable dose of glimepiride 4 – 8 mg QD for ≥10 weeks + 2 week run-in
2) placebo QD (106)
Lewin[64] US, Argentina, India, Japan, Hungary, Poland, Russia 18 245 DPP-4 1) linagliptin 5 mg QD (161); Unchanged from baseline SUb,c Stable SUc dose of ≥ half the maximum dose for 10 weeks (or documented maximum tolerated dose for ≥12 weeks) + 2 week run-in
2) placebo QD (84)
Strojek[31] Czech Republic, Hungary, Poland, Ukraine, Republic of Korea, Philippines, Thailand 24 597 SGLT2 1) dapagliflozin 2.5 mg QD (154); Glimepiride 4 mg QD, reduced to 2 mg QD or discontinued if hypoglycaemia occurred Stable SUc dose of ≥ half the maximum dose for 8 weeks. Continued on or switched to glimepiride 4 mg/day during an 8 week run-in
2) dapagliflozin 5 mg QD (145);
3) dapagliflozin 10 mg QD (151);
4) placebo QD (146)
  1. aStudy arms in italics were not included in the meta-analysis (not EU licensed dose); bDown-titration allowed in response to hypoglycaemia; cSU not specified in the publication; dStrata 1 (glimepiride only subgroup) n = 212, full trial population n = 441; BID, twice daily; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1 analogues; NMA, network meta-analysis; QD, once daily; SGLT2, sodium glucose co-transporter 2 inhibitors; SU, sulfonylurea.